BIOMIMESYS® Oncology is a Hyaluronic acid (HA) based scaffold 3D cell culture model. This groundbreaking 3D cell culture technology associates the behavior of a solid scaffold and of a hydrogel, which we call “Hydroscaffold”. The Hydroscaffold’s composition and mechanical properties can mimics the microenvironment of tumor cells. This scaffold provided cell binding sites with CD44 and RHAMM allowing cell-matrix and cell-cell interactions. Also, proven to provide better in vitro/in vivo correlation than 2D models.
Better reproducibility of mechanical stress on cells
Mechanical stress in solid tumors can impede drug delivery and may additionally drive tumor progression and promote metastasis. Mechanistically, biomechanical forces can drive tumor aggression by inducing a mesenchymal-like switch in transformed cells so that they attain tumor-initiating or stem-like cell properties. ¹ (Northey et al, 2017)
Above shows the increase in cellular proliferation in response to mechanical stress (2x in stiffness) of 3D matrices. Mechanical stress on cells can be mimicked by increasing in solid fiber (GAGs and collagens) concentration with BIOMIMESYS ®. This cannot be reproduced on 2D or 3D cell culture using hydrogels or Matrigel.
Better in vitro/in vivo correlation
By using BIOMIMESYS® Oncology, anti-oncogenic drugs (such as 5-Fluorouracil, 5-FU) showed cytotoxic effects closer to human responses compared to 2D culture.
Ready to use
BIOMIMESYS® Oncology is EASY & READY TO USE. Upon receiving the vacuum sealed 96-well plate open it (under a hood) and add the cells directly on top of the matrix. Changing the culture medium is easy as well. To remove medium, simply draw the medium with a pipette between the matrix and the edge of the well. To refresh the medium, place fresh medium onto the surface of the matrix.
Successfully Tested Cells
Human brain metastasis: SA87
Human breast adenocarcinoma : MCF-7
Human breast carcinoma : CAL-51
Human cervix adenocarcinoma : HeLa
Human colorectal adenocarcinoma : DLD-1, HT29, Caco-2
Human glioblastoma : CB109 / CB74 / CB191
Human liver hepatocellular carcinoma : HepG2
Human liver hepatoma : PLC / PRF-5
Human lung carcinoma : NCI-H460
Human osteosarcoma : SaOs
Human ovarian carcinoma : IGROV-1
Human pancreas carcinoma : PANC-1
Human prostate cancer : PC3
Normal human colon fibroblast : CCD18-co
Hematopoietic : CD34+
Human induced pluripotent stem cells : hiPS
Complete List of Tested Cells [PDF]
Compatible with Most Downstream Applications
BIOMIMESYS® hydroscaffold has many properties (transparent, porous, biodegradable, & solid) making it ideal for use with numerous downstream applications.
- Hyaluronic acid (HA) (1.6MDa) – Provides binding sites for CD44 and RHAMM cell surface receptors
- Adipic acid dihydrazide (ADH) as crosslinker
- Collagen Type I
- Young’s modulus: 1.1kPa – different stiffness is available by customization
- Porosity: 155±35µm
24 Hydrogel / 96 Well
- SKU: BIO_ONC_96_24_transp
- SKU: BIO_ONC_96_24_black
96 Hydrogel / 96 Well
- SKU: BIO_ONC_96_96_transp
- SKU: BIO_ONC_96_96_black
384 Hydrogel / 384 Well / Black
- SKU: BIO_ONC_384_384_black
- SKU: BIO_ONC_384_384_black_5
References & Literature
1. Bubba, F. et al. A chemotaxis-based explanation of spheroid formation in 3D cultures of breast cancer cells. Journal of Theoretical Biology 479, 73–80 (2019) doi: 10.1016/j.jtbi.2019.07.002.
2. Lane, R. et al. Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. Communications Biology 2, 315 (2019) doi: 10.1038/s42003-019-0560-x.
3. Gomes, A. et al. Evaluation by quantitative image analysis of anticancer drug activity on multicellular spheroids grown in 3D matrices. Oncol Lett 12, 4371–4376 (2016) doi: 10.3892/ol.2016.5221.
4. Salaroglio, I. C. et al. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. Journal of Experimental & Clinical Cancer Research 37, 286 (2018) doi: 10.1186/s13046-018-0967-0.
5. Vitali, E. et al. Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment. Cancers 12, (2020) doi: 10.3390/cancers12082143.
6. Salaroglio, I. C. et al. PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy. Molecular Cancer 16, 91 (2017) doi: 10.1186/s12943-017-0657-0.
7. Simon, T. et al. Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma. Molecular Cancer 17, 132 (2018) doi: 10.1186/s12943-018-0878-x.
8. Northey, J. J., Przybyla, L. & Weaver, V. M. Tissue Force Programs Cell Fate and Tumor Aggression. Cancer Discov 7, 1224 (2017) doi: 10.1158/2159-8290.CD-16-0733.
FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES